Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES-2 clinical study of ARO-ANG3 for mixed dyslipidemia